AZN: AstraZeneca PLC - Summary | Jitta

AstraZeneca PLC

NASDAQ:AZN

Price
$65.93
Loss Chance
47.7%
5.38JITTA SCORE
968.52%Over Jitta Line
Jitta Ranking
458 / 1,127
3,229 / 4,938
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (53)
Recent Business Performance (43)
Financial Strength (73)
Return to Shareholders (45)
Competitive Advantage (65)
Jitta Signs
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Revenue and EarningRevenue decline from 2018-2023
Operating MarginInconsistent
Recent Business PerformanceEarning decline 73.96% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.38
968.52%
2.10
194.51%
2.06
244.26%
Pharmaceuticals
6.91
46.87%
3.25
47.20%
3.88
30.11%
COMPANY DESCRIPTION
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.